Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285126 | 0.86 | ALDH1A1 (0.50) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3582052 | 0.81 | KDM4E (0.47) | LMNAHTTALDH1A1SMN1; SMN2BRD4 | |
| SCHEMBL8233143 | 0.76 | ALDH1A1 (0.58) | LMNAHTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3574450 | 0.74 | NOTUM (0.41) | HTTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3576688 | 0.72 | LMNA (0.46) | LMNAHTTALDH1A1BRD4BRD2 | |
| SCHEMBL8232729 | 0.71 | ALDH1A1 (0.60) | LMNAHTTALDH1A1MEN1KMT2A | |
| SCHEMBL9354368 | 0.70 | ALDH1A1 (0.70) | LMNAHTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL11719377 | 0.69 | P2RX3 (0.54) | LMNAHTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25271993 | 0.69 | GSK3A (0.46) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2435199 | 0.69 | GAA (0.64) | LMNAHTTALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104670-B3 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2104670-B1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMACEUTICALS SA (CH) | 2016-02-17 | — | — | EP | disclosed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | disclosed |
| US-8779129-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-2662366-A1 | Novel triazinedione derivatives as GABA-B receptor modulators | ADDEX Pharma S.A. (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2013-05-16 | — | — | US | disclosed |
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-2104670-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | Addex Pharma SA (CH) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008056257-A2 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABA-B RECEPTOR MODULATORS | ADDEX PHARMA S.A (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | LMNA 3784/4885HTT 3215/4885ALDH1A1 3515/4885 |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | LMNA 3784/4885HTT 3215/4885ALDH1A1 3515/4885 |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | LMNA 3784/4885HTT 3215/4885ALDH1A1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.